The first clinical trial of an extended-release formulation of travoprost shows it’s comparable to topical once-daily travoprost in patients with glaucoma.
To determine whether the efficacy and safety achieved with monthly ranibizumab as treatment for diabetic macular edema (DME) can be maintained with less-than-monthly treatment.
A complete work-up immediately following nonarteritic central retinal artery occlusion picks up undiagnosed cardiovascular risk factors in almost 80% of patients.
We extend our deepest gratitude to our Platinum, Gold, and Silver partners. Your generous support fuels our mission to advance medical education, advocate for patient safety, and foster breakthrough innovations across West Virginia.